middle.news
Vectus Validates Fibrosis Drug Safety, Eyes Licensing Deals in China and Beyond
6:06pm on Thursday 31st of July, 2025 AEST
•
Healthcare
Read Story
Vectus Validates Fibrosis Drug Safety, Eyes Licensing Deals in China and Beyond
6:06pm on Thursday 31st of July, 2025 AEST
Key Points
VB0004 safety profile further validated by recent Phase Ia/Ib clinical data
Active licensing discussions underway with global and Chinese partners
Production of VB0004 successfully validated in China for accelerated approval
Operating costs significantly reduced to focus on commercialisation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vectus Biosystems (ASX:VBS)
OPEN ARTICLE